Attralus

Attralus is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, developing transformative medicines for patients with systemic amyloidosis. Its proprietary pan-amyloid removal (PAR) platform pairs a pan-amyloid binding peptide with a humanized IgG1 monoclonal antibody so the resulting fusion protein binds amyloid deposits across every amyloidosis type and stage and recruits the immune system to clear them. The lead candidate, zamubafusp alfa (AT-02), is a pan-amyloid depleter in a Phase 1/2 open-label extension study and has received U.S. FDA Orphan Drug Designation for the treatment of AL amyloidosis; a next-generation PAR program (IV and subcutaneous) and a research-stage neurodegeneration program targeting Abeta, tau and alpha-synuclein aggregates follow behind it. Attralus' molecular imaging agents AT-01 (124-iodine evuzamitide) and AT-05 (99mTc-p5+14) were acquired by Bayer in January 2026. The company was launched in 2020 with a Series A from venBio Partners and has since raised additional rounds including a $56 million financing led by Alpha Wave Ventures with participation from Bristol Myers Squibb. Attralus is a therapeutics developer, not a software vendor: it publishes no developer portal, no public API, no SDKs and no machine-readable API contract of any kind (every OpenAPI, GraphQL, MCP, A2A and /.well-known/ path probed on its hosts returns 404, and no api/developer/docs subdomain resolves).

Attralus is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Health.

Attralus’ developer surface includes support and 17 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0

0 APIs

Company Biotechnology Pharmaceuticals Life Sciences Health Clinical Trials Therapeutics Rare DiseaseAmyloidosisMonoclonal AntibodiesMolecular ImagingNeurodegeneration Drug Development

Kin Score

Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0

Composite quality — 10.0/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.8 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/attralus: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 7

The organization behind the API

Website

About

Press

PressRSS

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 5

Properties that don't map to a standard resource type

SecondaryMarket

Science

Pipeline

Resources

Publications

Source (apis.yml)

aid: attralus
name: Attralus
description: 'Attralus is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, developing
  transformative medicines for patients with systemic amyloidosis. Its proprietary pan-amyloid removal (PAR) platform pairs
  a pan-amyloid binding peptide with a humanized IgG1 monoclonal antibody so the resulting fusion protein binds amyloid deposits
  across every amyloidosis type and stage and recruits the immune system to clear them. The lead candidate, zamubafusp alfa
  (AT-02), is a pan-amyloid depleter in a Phase 1/2 open-label extension study and has received U.S. FDA Orphan Drug Designation
  for the treatment of AL amyloidosis; a next-generation PAR program (IV and subcutaneous) and a research-stage neurodegeneration
  program targeting Abeta, tau and alpha-synuclein aggregates follow behind it. Attralus'' molecular imaging agents AT-01
  (124-iodine evuzamitide) and AT-05 (99mTc-p5+14) were acquired by Bayer in January 2026. The company was launched in 2020
  with a Series A from venBio Partners and has since raised additional rounds including a $56 million financing led by Alpha
  Wave Ventures with participation from Bristol Myers Squibb. Attralus is a therapeutics developer, not a software vendor:
  it publishes no developer portal, no public API, no SDKs and no machine-readable API contract of any kind (every OpenAPI,
  GraphQL, MCP, A2A and /.well-known/ path probed on its hosts returns 404, and no api/developer/docs subdomain resolves).'
url: https://raw.githubusercontent.com/api-evangelist/attralus/refs/heads/main/apis.yml
image: https://attralus.com/wp-content/uploads/2023/03/logo-color.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass
specificationVersion: '0.23'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Health
- Clinical Trials
- Therapeutics
- Rare Disease
- Amyloidosis
- Monoclonal Antibodies
- Molecular Imaging
- Neurodegeneration
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://attralus.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/attralus_stock/
- type: About
  url: https://attralus.com/company
- type: Science
  url: https://attralus.com/science
- type: Pipeline
  url: https://attralus.com/pipeline
- type: Resources
  url: https://attralus.com/amyloidosis
- type: Press
  url: https://attralus.com/press-releases
- type: PressRSS
  url: https://attralus.com/feed/
- type: Publications
  url: https://attralus.com/posters-and-publications
- type: Careers
  url: https://attralus.com/careers
- type: Contact
  url: https://attralus.com/contact
- type: Support
  url: https://attralus.com/contact
- type: TermsOfService
  url: https://attralus.com/terms-of-service
- type: PrivacyPolicy
  url: https://attralus.com/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/attralus/
- type: Twitter
  url: https://x.com/attralus
- type: LLMsTxt
  url: llms/attralus-llms.txt
- type: DomainSecurity
  url: security/attralus-domain-security.yml
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 2
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/attralus"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/attralus/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/attralus/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.